Aspergilloma pada Tuberkulosis Paru

Soedarsono Soedarsono, Elisabeth Tri Wahyuni Widoretno

= http://dx.doi.org/10.20473/jr.v3-I.2.2017.58-65
Abstract views = 171 times | views = 788 times

Abstract


The incidence of lung aspergillosis increases year to year. Lung aspergilloma is the most recognizable form of aspergillosis. Since 1980, the most common condition for initiating aspergillosis is tuberculosis (TB). Untreated pulmonary TB can cause several complications, such as decreases of pulmonary function, persistent pulmonary symptoms and Chronic Pulmonary Aspergillosis (CPA). More than 90% Aspergillosis is caused by Aspergillus fumigatus, this type is also widely found in people with TB. This type of fungus has a simple biological cycle with high sporulation capacity, which causes the release of conidia into the atmosphere with high concentrations. Humans inhale hundreds of conidia each day. Immuno competent hosts are capable of destroying conidia with the pulmonary immune system. Aspergillus infections cause illness when the host response is too strong or weak to the aspergillus antigen. The CPA morbidity rate is quite large with systemic symptoms and respiratory symptoms due to progressive pulmonary fibrosis and diminished lung function. During treatment, the CPA has a fatality rate of 20-33% in the short term and more than 50% in the span of 5 years. The Research Committee of the British Tuberculosis Association found that patients with post-TB cavity had a high risk of fungal colonization. The cavity formed in pulmonary TB is a suitable place for the development of various organisms including the fungus because it contains enough oxygen and necrotic tissue. The most common form of CPA associated with TB is Aspergilloma. In this review we will focus on aspergilloma, its diagnosis and management.

Keywords


Aspergilloma, Tuberculosis, Aspergillus fumigatus, Conidia, Cavity

Full Text:

PDF

References


Passera E, Rizzi A, Robustellini M, Rossi G, Pona CD, et al. Pulmonary aspergilloma: Clinical aspects and surgical treatment outcome. Thorac Surg Clin. 2012; 22: 345–361.

Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ, 2011; 89: 864–872.

Hayes GE, Frazer LN. Chronic Pulmonary Aspergillosis; Where are we, and where are we going. J. Fungi. 2016; 2(18): 1–34.

Mathavi S, Shankar R, Sasikala G, Kavitha A. A study on mycotic infection amomg sputum positive pulmonary tuberculosis patients in Salem district. Indian journal of researh. 2015 July; 4(7): 299–302.

Barnes PD, Marr KA. Aspergillosis: Spectrum of diasease, diagnosis, and treatment. Infectious Disease Clinics of North America. 2016; 20: 545–561.

Chamilos G, Kontoyiannis DP. Aspergillus, candida, and other opportunistic mold infections of the lung. Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM et al. Fishman’s pulmonary diseases and disorders. Edisi 4. Philadelphia: McGraw-Hill, 2008. h. 2291–2313.

Hohl TM, Feldmesser M. Aspergillus fumigatus: Principles of pathogenesis and host defense. Eukaryotic Cell. 2007; 6(11): 1953–1963.

Romani L. Immunity to fungal infections. Nat. Rev. Immunol. 2011; 11: 275–288. 9. Park S, Mehrad B. Innate imunity to aspergillus species. Clinical microbiology reviews. 2009; 22(4): 535–551.

Moodley L, Pillay J, Dheda K. Aspergilloma and the surgeon. J Thorac Dis 2014; 6(3): 202–209.

Shibuya K, Ando T, Hasegawa C,Wakayama M, Hamatani S, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother. 2004; (10): 138–145.

Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016; 47: 45–68

Panda BN. Fungal Infection of Lungs: The Emerging Scenario. Indian Journal of Tuberculosis. 2004; 51: 63–69.

Ricardson MD, Warnock DW. Fungal infection: Diagnosis and management: Blackwell scientific publication; 1993.

Franquet T, Muller NL, Gimenez A, Guembe P. Spectrum of Pulmonary Aspergillosis: Histologic, Clinical, and Radiologic Findings. RSNA. 2001 July–August; 21 (4): 825–837.

Patterson KC, Strek ME. Diagnosis and Treatment of Pulmonary Aspergillosis Syndrome. Chest. 2014 November; 146 (5): 1358–1368.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Jurnal Respirasi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

View My Satats

Indexed by: